Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
42.45
-0.35 (-0.82%)
At close: Jun 8, 2026, 4:00 PM EDT
42.00
-0.45 (-1.06%)
After-hours: Jun 8, 2026, 7:08 PM EDT
Alkermes Employees
Alkermes had 2,050 employees as of December 31, 2025. The number of employees increased by 250 or 13.89% compared to the previous year.
Employees
2,050
Change (1Y)
250
Growth (1Y)
13.89%
Revenue / Employee
$762,098
Profits / Employee
$74,498
Market Cap
7.08B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,050 | 250 | 13.89% |
| Dec 31, 2024 | 1,800 | -300 | -14.29% |
| Dec 31, 2023 | 2,100 | -180 | -7.89% |
| Dec 31, 2022 | 2,280 | 69 | 3.12% |
| Dec 31, 2021 | 2,211 | -34 | -1.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,527 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Neurocrine Biosciences | 2,000 |
| Lantheus Holdings | 1,193 |
| Supernus Pharmaceuticals | 778 |
ALKS News
- 4 days ago - Alkermes to present new data on Alixorexton, LUMRYZ - TheFly
- 4 days ago - Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research - Business Wire
- 5 days ago - Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 13 days ago - Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting - Business Wire
- 18 days ago - Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences - Business Wire
- 26 days ago - Alkermes price target raised to $48 from $45 at Baird - TheFly
- 26 days ago - Alkermes Proxy statement: Proxy filing - Filings
- 27 days ago - Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study - TheFly